ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0664

Development of a Novel Gene Expression-based Molecular Score That Characterizes Individual Lupus Patients

Prathyusha Bachali1, Erika Hubbard2, Kathryn Kingsmore Allison2, Yisha He2, Amrie Grammer3 and Peter Lipsky2, 1AMPEL BioSolutions, Redmond, WA, 2AMPEL BioSolutions, Charlottesville, VA, 3AMPEL LLC, Charlottesville, VA

Meeting: ACR Convergence 2022

Keywords: Gene Expression, informatics, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Etiology and Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Patients with SLE can exhibit considerable clinical heterogeneity. A robust patient stratification approach can help to characterize individual lupus patients more effectively based on their molecular profile. Machine learning (ML) and analysis of molecular profiles can help to classify lupus patients more precisely, but proper validation is required for clinical implementation of these methods by rheumatologists.

Methods: This study comprised 3,166 lupus samples extracted from 17 lupus blood gene expression datasets. Gene set variation analysis (GSVA) was carried out on each normalized dataset using 32 cell and process gene modules and resulting module enrichment scores were used as input into stable k-means clustering to subset lupus patients based on their gene expression profiles. We employed five different classification models including logistic regression (LR), Support Vector Machine (SVM), random forest (RF), and neural network to classify the lupus patients into patient subsets determined by k-means. The OnevsOne multi-class classification approach was used to avoid class imbalance. SHapley Additive exPlanations (SHAP) values were calculated for each patient subset to determine the most important features used in model prediction. The abnormalities of each lupus subset were summarized by a composite score developed by ridge regression modeling.

Results: Implementation of stable k-means clustering with the elbow method on GSVA scores of 3,166 lupus profiles identified eight subsets of lupus patients (Fig. 1). To evaluate and validate the classifiers, the trained models were applied to unseen data from 13 independent datasets. Among the four classifiers, SVM and LR performed best, with high degrees of accuracy (98%), precision (94%), sensitivity, and specificity (Fig. 2A-C). SHAP identified the IFN, monocyte, and anti-inflammation modules as the top contributors for classification of the lupus subsets (Fig. 2D). A composite molecular score, which comprised aggregate molecular scores of each GSVA gene module, was developed by ridge regression modeling and allowed for calculation of a molecular score for each lupus patient (Fig. 3A). A subset of patients was identified whose molecular scores were not different than those found in normal subjects, whereas other subsets of lupus patients had progressively higher scores indicative of the aggregation of molecular abnormalities. The composite molecular scores were significantly correlated with both anti-DNA titers and SLEDAI (Fig. 3B-C)

Conclusion: Altogether, the separation of lupus patients into molecular subsets was reproducible across 17 datasets. ML and SHAP allowed for the identification of key features necessary for the classification of distinct subsets of lupus patients and ridge regression permitted reduction of gene expression profiles to a score to assess lupus-related immune activity that correlated with clinical features. The implementation of a molecular score may provide a means to categorize lupus patients numerically based on the nature of each individual’s underlying molecular abnormalities.

Supporting image 1

Figure 1. Stable k-Means clustering analysis of 3,166 samples reveals eight lupus subsets. Heatmap of k-means clustering using GSVA enrichment scores for 32 cell and pathway modules (rows) in 3,166 samples (columns).

Supporting image 2

Figure 2. Machine learning algorithms can predict lupus subset memberships with high accuracy and identify the key contributors. Area under the ROC curve (AUC), performance metrics, and confusion matrices of each of 3 classifiers are summarized: (A) support vector machine, (B) logistic regression, and (C) random forest. Each model was trained and validated on 2,183 samples and tested on the 13 independent datasets (n=983). (D) Top 20 key contributors identified by SHapley Additive exPlanations (SHAP).

Supporting image 3

Figure 3. Gene expression-based molecular score as a metric to determine lupus patient disease severity. (a) The mean + SEM (top) and distribution (bottom) of the composite molecular score for the six molecular subsets in GSE88884. Statistical differences between mean scores of the molecular subsets were evaluated with Kruskal-Wallis test with Dunn’s multiple comparisons. Linear regression between (b) SLEDAI or (c) Anti-dsDNA and the molecular score.


Disclosures: P. Bachali, None; E. Hubbard, None; K. Kingsmore Allison, None; Y. He, None; A. Grammer, None; P. Lipsky, None.

To cite this abstract in AMA style:

Bachali P, Hubbard E, Kingsmore Allison K, He Y, Grammer A, Lipsky P. Development of a Novel Gene Expression-based Molecular Score That Characterizes Individual Lupus Patients [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/development-of-a-novel-gene-expression-based-molecular-score-that-characterizes-individual-lupus-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-a-novel-gene-expression-based-molecular-score-that-characterizes-individual-lupus-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology